Sivik Global Healthcare’s Coherus Oncology CHRS Stock Holding History

Sivik Global Healthcare’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-45,296	Closed	-$918K	–	54
2019 Q3	$918K	Sell	45,296 -99,704	-69%	-$1.99M	0.46%	43
2019 Q2	$3.2M	Sell	145,000 -80,000	-36%	-$1.39M	0.77%	38
2019 Q1	$3.07M	Buy	+225,000	New	+$3M	1.13%	42
2018 Q4	–	Sell	-99,101	Closed	-$1.64M	–	54
2018 Q3	$1.64M	Sell	99,101 -899	-0.9%	-$15.9K	0.58%	54
2018 Q2	$1.4M	Buy	+100,000	New	+$1.43M	0.54%	56

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sivik Global Healthcare's CHRS Position: Q4 2019 in Review

Sivik Global Healthcare sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 45,296 shares — an estimated $918K sold.

Sivik Global Healthcare first reported a position in CHRS in Q2 2018 and held it in 5 quarters. The position peaked at $3.2M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

Sivik Global Healthcare reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
Sivik Global Healthcare sold 45,296 Coherus Oncology shares in Q4 2019, an estimated $918K.
Sivik Global Healthcare first reported a position in Coherus Oncology in Q2 2018 and held it in 5 quarters.
Sivik Global Healthcare's Coherus Oncology position peaked at $3.2M in Q2 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Sivik Global Healthcare's 13F filing for Q4 2019, filed 13 Feb 2020.